Although the clinical trial of XEN496, an ezogabine-like drug for KCNQ2-related DEE (NCT04639310), was terminated, other potassium channel openers, such as XEN1101 and BHV-7000, are being evaluated in broader epilepsy populations [51,52]. Here, KCNQ2 is linked to developmental and epileptic encephalopathy.